Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

E. Brissot, M. Labopin, M. Stelljes, G. Ehninger, R. Schwerdtfeger, J. Finke, HJ. Kolb, A. Ganser, K. Schäfer-Eckart, AR. Zander, D. Bunjes, S. Mielke, WA. Bethge, N. Milpied, P. Kalhs, IW. Blau, N. Kröger, A. Vitek, M. Gramatzki, E. Holler, C....

. 2017 ; 10 (1) : 130. [pub] 20170624

Language English Country Great Britain

Document type Comparative Study, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18010459

BACKGROUND: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased availability of unrelated donors together with the significant reduction in transplant-related mortality in recent years have opened the possibility for transplantation to a larger number of patients with PRF-AML. Moreover, transplant from unrelated donors may be associated with stronger graft-mediated anti-leukemic effect in comparison to transplantations from HLA-matched sibling donor, which may be of importance in the setting of PRF-AML. METHODS: The current study aimed to address the issue of HSCT for PRF-AML and to compare the outcomes of HSCT from matched sibling donors (n = 660) versus unrelated donors (n = 381), for patients with PRF-AML between 2000 and 2013. The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. RESULTS: HSCT provide patients with PRF-AML a 2-year leukemia-free survival and overall survival of about 25 and 30%, respectively. In multivariate analysis, two predictive factors, cytogenetics and time from diagnosis to transplant, were associated with lower leukemia-free survival, whereas Karnofsky performance status at transplant ≥90% was associated with better leukemia-free survival (LFS). Concerning relapse incidence, cytogenetics and time from diagnosis to transplant were associated with increased relapse. Reduced intensity conditioning regimen was the only factor associated with lower non-relapse mortality. CONCLUSIONS: HSCT was able to rescue about one quarter of the patients with PRF-AML. The donor type did not have any impact on PRF patients' outcomes. In contrast, time to transplant was a major prognostic factor for LFS. For patients with PRF-AML who do not have a matched sibling donor, HSCT from an unrelated donor is a suitable option, and therefore, initiation of an early search for allocating a suitable donor is indicated.

Acute Leukemia Working Party Office Hôpital Saint Antoine APHP Paris France Chaim Sheba Medical Center Tel Hashomer Israel

Bone Marrow Transplantation Center University Hospital Eppendorf Hamburg Germany

Charite Campus Benjamin Franklin Universitaetsmedizin Berlin Klinik 3 Hematologie u Onkologie Hindenburgdamm Berlin Germany

Department of Clinical Hematology Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Haematology Oncology University Hospital Regensburg Regensburg Germany

Department of Hematology Hemostasis Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany

Department of Internal Medicine 1 Bone Marrow Transplantation Unit Medical University of Vienna Vienna Austria

Department of Internal Medicine 2 Würzburg University Medical Center Würzburg Germany

Department of Medicine A Hematology and Oncology University of Muenster Muenster Germany

Department of Stem Cell Transplantation University Medical Center Hamburg Eppendorf Hamburg Germany

Deutsche Klinik für Diagnostik KMY Zentrum Wiesbaden Germany

Division of Stem Cell Transplantation and Immunotherapy University of Kiel Kiel Germany

Faculty of Medicine and Medical Center Hematology Oncology and Stem Cell Transplantation University of Freiburg Freiburg im Breisgau Germany

Hematology CHU de Bordeaux Bordeaux France

Hospital Clinic Institut d'investigacions Biomèdiques August Pi i Sunyer Barcelona Spain

Klinik fuer Innere Medizin 3 Universtätklinikum Ulm Germany

Klinikum Grosshadern Med Klinik 3 München Germany

Medical Department Hematology and Oncology University of Tuebingen Tübingen Germany

Medizinische Klinik Klinikum Augsburg Germany

Medizinische Klinik und Poliklinik 1 Universitätsklinikum Dresden Germany

Medizische Klinik Paracelsus Medizinische Privatuniversität Nürnberg Germany

Service d'Hématologie Clinique et de Thérapie Cellulaire Hôpital Saint Antoine APHP 184 rue du faubourg Saint Antoine 75571 Paris Cedex 12 France

Service d'Hématologie Clinique et de Thérapie Cellulaire Hôpital Saint Antoine APHP 184 rue du faubourg Saint Antoine 75571 Paris Cedex 12 France Acute Leukemia Working Party Office Hôpital Saint Antoine APHP Paris France

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010459
003      
CZ-PrNML
005      
20240528155253.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13045-017-0498-8 $2 doi
035    __
$a (PubMed)28646908
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Brissot, Eolia $u Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du faubourg Saint-Antoine, 75571, Paris, Cedex 12, France. eolia.brissot@gmail.com.
245    10
$a Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT / $c E. Brissot, M. Labopin, M. Stelljes, G. Ehninger, R. Schwerdtfeger, J. Finke, HJ. Kolb, A. Ganser, K. Schäfer-Eckart, AR. Zander, D. Bunjes, S. Mielke, WA. Bethge, N. Milpied, P. Kalhs, IW. Blau, N. Kröger, A. Vitek, M. Gramatzki, E. Holler, C. Schmid, J. Esteve, M. Mohty, A. Nagler,
520    9_
$a BACKGROUND: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased availability of unrelated donors together with the significant reduction in transplant-related mortality in recent years have opened the possibility for transplantation to a larger number of patients with PRF-AML. Moreover, transplant from unrelated donors may be associated with stronger graft-mediated anti-leukemic effect in comparison to transplantations from HLA-matched sibling donor, which may be of importance in the setting of PRF-AML. METHODS: The current study aimed to address the issue of HSCT for PRF-AML and to compare the outcomes of HSCT from matched sibling donors (n = 660) versus unrelated donors (n = 381), for patients with PRF-AML between 2000 and 2013. The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. RESULTS: HSCT provide patients with PRF-AML a 2-year leukemia-free survival and overall survival of about 25 and 30%, respectively. In multivariate analysis, two predictive factors, cytogenetics and time from diagnosis to transplant, were associated with lower leukemia-free survival, whereas Karnofsky performance status at transplant ≥90% was associated with better leukemia-free survival (LFS). Concerning relapse incidence, cytogenetics and time from diagnosis to transplant were associated with increased relapse. Reduced intensity conditioning regimen was the only factor associated with lower non-relapse mortality. CONCLUSIONS: HSCT was able to rescue about one quarter of the patients with PRF-AML. The donor type did not have any impact on PRF patients' outcomes. In contrast, time to transplant was a major prognostic factor for LFS. For patients with PRF-AML who do not have a matched sibling donor, HSCT from an unrelated donor is a suitable option, and therefore, initiation of an early search for allocating a suitable donor is indicated.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a přežívání štěpu $7 D006085
650    _2
$a nemoc štěpu proti hostiteli $x epidemiologie $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x epidemiologie $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sourozenci $7 D035781
650    _2
$a homologní transplantace $x škodlivé účinky $x metody $7 D014184
650    12
$a nepříbuzný dárce $7 D061349
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Labopin, Myriam $u Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du faubourg Saint-Antoine, 75571, Paris, Cedex 12, France. Acute Leukemia Working Party Office, Hôpital Saint Antoine, APHP, Paris, France.
700    1_
$a Stelljes, Matthias $u Department of Medicine A/Hematology and Oncology, University of Muenster, Muenster, Germany.
700    1_
$a Ehninger, Gerhard $u Medizinische Klinik und Poliklinik I, Universitätsklinikum, Dresden, Germany.
700    1_
$a Schwerdtfeger, Rainer $u Deutsche Klinik für Diagnostik, KMY, Zentrum, Wiesbaden, Germany.
700    1_
$a Finke, Jürgen $u Faculty of Medicine and Medical Center, Hematology, Oncology and Stem Cell Transplantation, University of Freiburg, Freiburg im Breisgau, Germany.
700    1_
$a Kolb, Hans-Jochem $u Klinikum Grosshadern, Med. Klinik III, München, Germany.
700    1_
$a Ganser, Arnold $u Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
700    1_
$a Schäfer-Eckart, Kerstin $u Medizische Klinik, Paracelsus Medizinische Privatuniversität, Nürnberg, Germany.
700    1_
$a Zander, Axel R $u Bone Marrow Transplantation Center, University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Bunjes, Donald $u Klinik fuer Innere Medizin III, Universtätklinikum, Ulm, Germany.
700    1_
$a Mielke, Stephan $u Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany.
700    1_
$a Bethge, Wolfgang A $u Medical Department, Hematology and Oncology, University of Tuebingen, Tübingen, Germany.
700    1_
$a Milpied, Noël $u Hematology, CHU de Bordeaux, Bordeaux, France.
700    1_
$a Kalhs, Peter $u Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria.
700    1_
$a Blau, Igor-Woflgang $u Charite-Campus Benjamin Franklin Universitaetsmedizin Berlin Klinik III- Hematologie u Onkologie, Hindenburgdamm, Berlin, Germany.
700    1_
$a Kröger, Nicolaus $u Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Vitek, Antonin $u Department of Clinical Hematology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Gramatzki, Martin $u Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany.
700    1_
$a Holler, Ernst $u Department of Haematology/Oncology, University Hospital Regensburg, Regensburg, Germany.
700    1_
$a Schmid, Christoph $u Medizinische Klinik Klinikum, Augsburg, Germany.
700    1_
$a Esteve, Jordi $u Hospital Clinic Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
700    1_
$a Mohty, Mohamad $u Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du faubourg Saint-Antoine, 75571, Paris, Cedex 12, France. Acute Leukemia Working Party Office, Hôpital Saint Antoine, APHP, Paris, France. $7 xx0317729
700    1_
$a Nagler, Arnon $u Acute Leukemia Working Party Office, Hôpital Saint Antoine, APHP, Paris, France. Chaim Sheba Medical Center, Tel Hashomer, Israel.
773    0_
$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 10, č. 1 (2017), s. 130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28646908 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20240528155249 $b ABA008
999    __
$a ok $b bmc $g 1287944 $s 1007271
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 10 $c 1 $d 130 $e 20170624 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options